Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse.
Trewin BP, Dale RC, Qiu J, Chu M, Jeyakumar N, Dela Cruz F, Andersen J, Siriratnam P, Ma KKM, Hardy TA, van der Walt A, Lechner-Scott J, Butzkueven H, Broadley SA, Barnett MH, Reddel SW, Brilot F, Kalincik T, Ramanathan S; Australasian MOGAD Study Group. Trewin BP, et al. Among authors: dela cruz f. J Neurol Neurosurg Psychiatry. 2024 Oct 16;95(11):1054-1063. doi: 10.1136/jnnp-2024-333463. J Neurol Neurosurg Psychiatry. 2024. PMID: 38744459 Free PMC article.
The clinical relevance of MOG antibody testing in cerebrospinal fluid.
Reynolds M, Tan I, Nguyen K, Merheb V, Lee FXZ, Trewin BP, Lerch M, Shah S, Wolfe N, Buzzard K, Lechner-Scott J, Fabis-Pedrini M, Fok A, John N, Kneebone C, Yiannikas C, Brown DA, Kermode AG, Reddel S, Dale RC, Brilot F, Ramanathan S; Australasian MOGAD Study Group. Reynolds M, et al. Ann Clin Transl Neurol. 2024 Sep;11(9):2514-2519. doi: 10.1002/acn3.52163. Epub 2024 Jul 28. Ann Clin Transl Neurol. 2024. PMID: 39073255 Free PMC article.
Lessons learned from 20 years of preclinical testing in pediatric cancers.
Smith MA, Houghton PJ, Lock RB, Maris JM, Gorlick R, Kurmasheva RT, Li XN, Teicher BA, Chuang JH, Dela Cruz FS, Dyer MA, Kung AL, Lloyd MW, Mossé YP, Stearns TM, Stewart EA, Bult CJ, Erickson SW. Smith MA, et al. Among authors: dela cruz fs. Pharmacol Ther. 2024 Dec;264:108742. doi: 10.1016/j.pharmthera.2024.108742. Epub 2024 Nov 5. Pharmacol Ther. 2024. PMID: 39510293 Free article. Review.
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial.
Gaspar N, Hung GY, Strauss SJ, Campbell-Hewson Q, Dela Cruz FS, Glade Bender JL, Koh KN, Whittle SB, Chan GC, Gerber NU, Palmu S, Morgenstern DA, Longhi A, Baecklund F, Lee JA, Locatelli F, Márquez Vega C, Janeway KA, McCowage G, McCabe MG, Bidadi B, Huang J, McKenzie J, Okpara CE, Bautista F; OLIE Study Investigators. Gaspar N, et al. Among authors: dela cruz fs. JAMA Oncol. 2024 Dec 1;10(12):1645-1653. doi: 10.1001/jamaoncol.2024.4381. JAMA Oncol. 2024. PMID: 39418029 Free PMC article. Clinical Trial.
Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials.
Metts JL, Aye JM, Crane JN, Oberoi S, Balis FM, Bhatia S, Bona K, Carleton B, Dasgupta R, Dela Cruz FS, Greenzang KA, Kaufman JL, Linardic CM, Parsons SK, Robertson-Tessi M, Rudzinski ER, Soragni A, Stewart E, Weigel BJ, Wolden SL, Weiss AR, Venkatramani R, Heske CM. Metts JL, et al. Among authors: dela cruz fs. Cancer. 2024 Nov 15;130(22):3785-3796. doi: 10.1002/cncr.35457. Epub 2024 Jun 28. Cancer. 2024. PMID: 38941509
Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials.
Reed DR, Tulpule A, Metts J, Trucco M, Robertson-Tessi M, O'Donohue TJ, Iglesias-Cardenas F, Isakoff MS, Mauguen A, Shukla N, Dela Cruz FS, Tap W, Kentsis A, Morris CD, Hameed M, Honeyman JN, Behr GG, Sulis ML, Ortiz MV, Slotkin E. Reed DR, et al. Among authors: dela cruz fs. J Clin Oncol. 2024 Sep 1;42(25):2955-2960. doi: 10.1200/JCO.23.02717. Epub 2024 Jun 6. J Clin Oncol. 2024. PMID: 38843482
Identification and Pharmacological Targeting of Treatment-Resistant, Stem-like Breast Cancer Cells for Combination Therapy.
Worley J, Noh H, You D, Turunen MM, Ding H, Paull E, Griffin AT, Grunn A, Zhang M, Guillan K, Bush EC, Brosius SJ, Hibshoosh H, Mundi PS, Sims P, Dalerba P, Dela Cruz FS, Kung AL, Califano A. Worley J, et al. Among authors: dela cruz fs. bioRxiv [Preprint]. 2024 May 16:2023.11.08.562798. doi: 10.1101/2023.11.08.562798. bioRxiv. 2024. PMID: 38798673 Free PMC article. Preprint.
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas.
Kazansky Y, Mueller HS, Cameron D, Demarest P, Zaffaroni N, Arrighetti N, Zuco V, Mundi PS, Kuwahara Y, Somwar R, Qu R, Califano A, de Stanchina E, Dela Cruz FS, Kung AL, Gounder MM, Kentsis A. Kazansky Y, et al. Among authors: dela cruz fs. bioRxiv [Preprint]. 2024 May 6:2024.05.03.592420. doi: 10.1101/2024.05.03.592420. bioRxiv. 2024. PMID: 38766189 Free PMC article. Preprint.
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.
Kazansky Y, Cameron D, Mueller HS, Demarest P, Zaffaroni N, Arrighetti N, Zuco V, Kuwahara Y, Somwar R, Ladanyi M, Qu R, de Stanchina E, Dela Cruz FS, Kung AL, Gounder MM, Kentsis A. Kazansky Y, et al. Among authors: dela cruz fs. Cancer Discov. 2024 Jun 3;14(6):965-981. doi: 10.1158/2159-8290.CD-23-0110. Cancer Discov. 2024. PMID: 38315003 Free PMC article.
96 results